Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 1st Preview)
-
AI-enabled chemical discovery infrastructure
Researchers at St. Jude Children’s Research Hospital, the University of Pavia, Dana-Farber Cancer Institute and Harvard Medical School unveiled AdaptiveFlow, an open-source, AI-informed platform published in Nature Biotechnology. The system is designed to virtually screen ultra-large libraries at much lower compute cost, enabling routine “ultralarge” searches that previously required prohibitive resources.
-
Federal push for on-demand RNA manufacturing
ARPA-H launched the Genetics Medicines and Individualized Manufacturing for Everyone (GIVE) program, committing up to $125 million to build a domestic network for automated, on-demand RNA drug manufacturing. The program aims to integrate near-point-of-care production with automated quality-control testing.
-
Regulatory and safety actions in cellular therapy
Novartis and Bristol Myers Squibb paused portions of their autoimmune CAR-T development after immune-related adverse events, according to separate reports. The pauses highlight continued safety scrutiny for autoimmune-directed engineered cell therapies and add uncertainty to timelines for multiple programs across the category.
-
Clinical efficacy signal in multiple sclerosis
Novartis said its BTK inhibitor remibrutinib (Rhapsido) showed “superiority” in two Phase 3 multiple sclerosis studies, reporting reduced annualized relapse rates and inflammatory brain lesions versus Aubagio. The company also said the results showed clinically meaningful effects on disability progression and did not worsen liver safety, a key issue for BTK inhibitors in MS development.
-
Biopharma licensing and anticancer innovation
Genentech and Dualitybio entered a collaboration and license agreement centered on the DUPAC platform for next-generation antibody-drug conjugates. The deal supports development of new ADC candidates designed to address resistance associated with older topoisomerase inhibitor payload approaches.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.